Literature DB >> 23966784

Facial expression in patients with bipolar disorder and schizophrenia in response to emotional stimuli: a partially shared cognitive and social deficit of the two disorders.

Giuseppe Bersani1, Elisa Polli, Giuseppe Valeriani, Daiana Zullo, Claudia Melcore, Enrico Capra, Adele Quartini, Pietropaolo Marino, Amedeo Minichino, Laura Bernabei, Maddalena Robiony, Francesco Saverio Bersani, Damien Liberati.   

Abstract

INTRODUCTION: It has recently been highlighted that patients affected by schizophrenia (SCZ) and those affected by bipolar disorder (BD) undergo gradual chronic worsening of cognitive and social functioning. The objective of the current study was to evaluate and compare (using the Facial Action Coding System [FACS]) the way by which patients with the two disorders experience and display emotions in relation to specific emotional stimuli.
MATERIALS AND METHODS: Forty-five individuals participated in the study: 15 SCZ patients, 15 BD patients, and 15 healthy controls. All participants watched emotion-eliciting video clips while their facial activity was videotaped. The congruent/incongruent feeling of emotions and the facial expression in reaction to emotions were evaluated.
RESULTS: SCZ and BD patients presented similar incongruent emotive feelings and facial expressions (significantly worse than healthy participants); SCZ patients expressed the emotion of disgust significantly less appropriately than BD patients. DISCUSSION: BD and SCZ patients seem to present a similar relevant impairment in both experiencing and displaying emotions; this impairment may be seen as a behavioral indicator of the deficit of social cognition present in both the disorders. As the disgust emotion is mainly elaborated in the insular cortex, the incongruent expression of disgust of SCZ patients can be interpreted as a further evidence of a functional deficit of the insular cortex in this disease. Specific remediation training could be used to improve emotion and social cognition in SCZ and BD patients.

Entities:  

Keywords:  FACS; bipolar disorder; facial expression; schizophrenia; social cognition

Year:  2013        PMID: 23966784      PMCID: PMC3743655          DOI: 10.2147/NDT.S46525

Source DB:  PubMed          Journal:  Neuropsychiatr Dis Treat        ISSN: 1176-6328            Impact factor:   2.570


Introduction

Schizophrenia (SCZ) and bipolar disorder (BD) are severe and disabling diseases. The main clinical features of the acute phases of the two disorders are very different; however, both disorders are characterized by gradual chronic worsening of cognitive and social functioning.1 Cognitive and social impairment of SCZ patients has been widely studied and described in the last decades.2 On the other hand, the course of BD has traditionally been viewed as episodic, with symptomatic and functional recovery between mood episodes;3 this view has recently been challenged by clinical and epidemiological studies that document how, despite symptomatic improvements, many individuals with BD experience difficulties in daily functioning also during recovery following mood episodes (for example, there are higher rates of unemployment and disability among individuals with BD than in the normal population).4–7 Cognitive and social impairments have nowadays been found in BD patients even during the euthymic phase of the disease, thus representing trait-associated, rather than state-associated, characteristics of the disorder.8,9 Social cognition (SC) is a multifaceted construct that focuses on how people process information within social contexts; it includes Theory of Mind (ToM), social knowledge/perception, attributional styles, and emotional processing.10,11 A large body of evidence indicates that both patients with SCZ and those with BD present deficits in some constructs of SC, including ToM and emotional processing, and that these deficits may underlie those areas of the disorders that usually persist despite pharmacological treatments, such as low social functioning, affective flattening, disability, and cognitive deficits.1,12–15 It has been repeatedly reported that SCZ patients show characteristic facial activities, such as reduced levels of facial expressivity in reaction to emotional stimuli and during social interactions; this reduction can be seen as a behavioral indicator of emotional processing deficits.12,16,17 As BD and SCZ seem to share complex chronic deficits in cognitive functioning and SC that are independent from acute psychopathological manifestations, the aim of the present study is to investigate if and/or to what extent BD patients present reduced levels of facial expressivity, as an index of emotional experiences, similarly to SCZ patients.

Materials and methods

Participants

The sample consisted of outpatients recruited at the Alfredo Fiorini Hospital of Terracina, Sapienza University of Rome, and 15 healthy controls. After having signed a written informed consent, patients underwent a structured clinical interview on the model of SCID-I (Structured Clinical Interview for DSM-IV Axis I Disorders) and, according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), they were divided into two groups: patients with SCZ (n = 15) and patients with BD Type I without psychotic symptoms (n = 15; Table 1). BD patients were in the euthymic phase of the disease while SCZ patients presented a chronic and stable clinical condition; healthy participants were selected to match demographics to the patient group.
Table 1

Study participants

Bipolar disorderSchizophreniaHealthy controlsP-value
Number of patients151515
Mean age (years)48.13 ± 10.6045.13 ± 12.6941.80 ± 12.500.39
Sex7 males, 8 females7 males, 8 females7 males, 8 females
Education (years)11.06 ± 2.2510.13 ± 3.0913.00 ± 4.220.06
Exclusion criteria were: significant concomitant neurological diseases, other Axis I diagnosis, tardive dyskinesia, history of abuse of alcohol or other drugs of abuse, hospitalization in the last 12 months, pharmacological treatment with typical antipsychotics, clinical onset within the previous 24 months, Hamilton Depression Rating Scale score >7 (for BD patients), young mania rating scale >11 (for BD patients), scores >4 for “delusions”, “conceptual disorganization”, and “hallucinations” items of the positive and negative syndrome scale (for SCZ patients). At the time of the assessment, all patients were on pharmacological treatment as requested by their clinical condition (Table 2).
Table 2

Number of patients treated with each medication

Schizophrenic patientsBipolar disorder patients
Valproate711
Aripiprazole62
Paliperidone40
Clozapine20
Risperidone21
Lithium13
Olanzapine12
Quetiapine12
Paroxetine10
Clomipramine12
Fluvoxamine10
Escitalopram10
Bupropione01
Gabapentin01
Fluoxetine01
Duloxetine01
Lamotrigine00

Facial Action Coding System and video clips

The Facial Action Coding System (FACS) by Ekman and Friesen18 is one of the most widely used instruments for the analysis of facial expression. It is based on an anatomical analysis of facial action through the codification of facial expression in 44 “action units” (AUs; Figure 1). AUs are anatomically defined; they represent the basic repertory of human facial expressions. Using the FACS, the variety of facial movements can be observed objectively.
Figure 1

Action units.

Abbreviations: AU, action units; Facs, Facial Action Coding System.

The FACS investigator’s guide19 codes the exact combinations of AUs that should be observed in response to each emotional stimulus (Figure 2).
Figure 2

Expected action units for each emotion.

Notes: *In this combination the AU may be at any intensity level. A–E represent the intensity of the action: A, Trace; B, Slight; C, Marked or Pronounced; D, Severe or Extreme; E, Maximum.

Abbreviations: AU, action units; R, actions only on the right side of the face; L, actions only on the left side of the face.

The use of video clips to elicit specific emotions has a long history in clinical psychology and psychiatry;20 Gross et al systematized this issue selecting and validating 16 films that successfully elicited amusement, anger, contentment, disgust, sadness, surprise, fear, and a neutral state.21 Video clip details are given in Table 3.
Table 3

Video clips used to elicit emotions

VideoDescriptionElicited emotionLength of film clip (minute:second)
Video 1: color barscolor barsNeutrality1:30
Video 2: When Harry Met SallyDiscussion of orgasm in caféAmusement2:35
Video 3: The ShiningBoy playing in hallwayFear1:22
Video 4: Capricorn OneAgents burst through doorSurprise0:49
Video 5: Cry FreedomPolice abuse protestersAnger2:36
Video 6: The champBoy cries at father’s deathSadness2:51
Video 7: Pink FlamingosPerson eats dog fecesDisgust0:30
Video 8: Roberto Benigni and MassimoComedy routineAmusement1:30
Troisi video interview

Study design

All patients watched video clips designed to elicit significant and specific emotions. The facial expression of each patient in response to the vision of the films was video recorded. These video clips, all in Italian, were watched by the three groups of subjects in the same order, according to the protocol established by Gross21 and according to the protocol of a previous study by our research team:22 video 1 = neutral; video 2 = amusement; video 3 = fear; video 4 = surprise; video 5 = anger; video 6 = sadness; video 7 = disgust; video 8 = amusement. Between single video clips, patients were asked to fill out a post film questionnaire to indicate what emotion they experienced in relation to the video (Table 4).22 Each response to the questionnaire was then scored in relation to the expected emotion.
Table 4

Post film questionnaire

EmotionVideo
12345678
Fear
Sadness
Happiness
Surprise
Anger
Disgust
Neutrality
Two different reports were produced. In the report of concordant responses, a score of 1 was given for each emotional report concordant with the expected emotion and a score of 0 was given if the patient reported to not have felt any emotion (neutrality) or to have felt an emotion different from that expected. Scores could range between a minimum of 0 and a maximum of 8; for example, patients obtained an 8 when they reported concordant emotions in response to all the 8 video clips. In the report of discordant responses, a score of 1 was given for each emotional report discordant with the expected emotion associated with the video clip and 0 if the patient reported to not have felt any emotion (neutrality). Scores could range between a minimum of 0 and a maximum of 8; for example, patients obtained the score 8 when they reported wrong emotions in response to all the 8 video clips. At the end of the film session, the mimic reactions to the video clips were coded following the indications of the FACS investigator’s guide.19 The same three examiners (EP, G V, DL) evaluated all video registrations. The three examiners previously attended a specific 3-day workshop organized by the Centro Ricerche FACS Onlus (CRF; FACS research center) at the University of Trieste. For the scoring it was considered the specific expected emotion associated to the video and the combination of AUs observed in response. Since each video was evocative of only one specific emotion, specific combinations of AUs were expected in relation to each video (Figure 2). If one of the expected combinations of AUs occurred, the examiners assigned the score 1; if the expected combinations did not occur the examiners assigned the score 0 (this scoring was repeated for each movie clip); for example, patients obtained the score 8 when they presented the expected facial expression (Figures 1 and 2) in response to all eight video clips.

Statistical analysis

The data were analyzed using SPSS software version 20 (IBM Corporation, Armonk, NY, USA). One-way univariate analysis of variance (ANOVA) was used to compare socio-demographic data of participants. In addition to descriptive statistics, one-way univariate ANOVA was performed to compare the mean scores of participants divided into diagnosis groups. As the diagnosis factor had more than two levels, post-hoc tests were calculated using the Bonferroni test. Chi-squared and Fisher’s exact test were used to compare the right or wrong facial expression in reaction to emotional stimuli of BD and SCZ patients.

Results

Post film questionnaire – concordant responses

One-way ANOVA determined statistically significant differences between group means (F2 = 25.39, P < 0.01). Mean score ± standard deviation of the report of concordant responses was 4.13 ± 1.50 for SCZ patients, 4.93 ± 1.75 for BD patients, and 7.53 ± 0.51 for healthy controls. Comparing between groups with the post-hoc Bonferroni test revealed that healthy controls had significantly higher scores than both SCZ (difference of means = 3.40; P<0.01) and BD patients (difference of means = 2.60; P < 0.01). There were not significant differences between SCZ and BD patients (P = 0.34; Figure 3).
Figure 3

Mean number of concordant responses in BD, SCZ, and control groups.

Note: *P < 0.05.

Abbreviations: BD, bipolar disorder; SCZ, schizophrenic; vs, versus.

Post film questionnaire - discordant responses

One-way ANOVA determined statistically significant differences between group means (F2 = 17.91, P < 0.01). Mean scores ± standard deviation of the report of discordant responses were 2.20 ± 1.26 for SCZ patients, 1.46 ± 1.24 for BD patients, and 0.00 ± 0.00 for healthy controls. Comparing between groups using the post-hoc Bonferroni test showed that healthy controls had significantly lower scores than both SCZ (difference of means = −2.20; P < 0.01) and BD patients (difference of means = −1.46; P < 0.01). There were no significant differences between SCZ and BD patients (P = 0.17; Figure 4).
Figure 4

Mean number of discordant responses in BD, SCZ, and control groups.

Note: *P < 0.05.

Abbreviations: BD, bipolar disorder; SCZ, schizophrenic; vs, versus.

Facial expressions

One-way ANOVA determined statistically significant differences between group means (F2 = 33.42, P < 0.01). Mean FACS score was 3.26 ± 1.53 for SCZ patients, 5.00 ± 1.51 for BD patients, and 7.13 ± 0.63 for healthy controls. Comparing between groups using the post-hoc Bonferroni test showed that the FACS score of SCZ patients was significantly lower than BD (difference of means = −1.73; P < 0.01) and healthy controls (difference of means = −3.86; P < 0.01). BD patients and healthy controls also had significantly different scores (different of means = 2.13; P < 0.01; Figure 5).
Figure 5

Mean Facs scores in BD, SCZ, and control groups.

Note: *P < 0.05.

Abbreviations: BD, bipolar disorder; Facs, Facial action coding system; SCZ, schizophrenic; vs, versus.

Facial expression in reaction to emotional stimuli in BD and SCZ patients

According to the FACS investigator’s guide, all BD and SCZ patients showed congruent facial expression in response to neutral stimuli, seven BD and two SCZ (P = 0.10) patients showed congruent facial expressions in response to fear stimuli, three BD and four SCZ (P = 0.45) patients showed congruent facial expressions in response to surprise stimuli, five BD and three SCZ (P = 0.68) patients showed congruent facial expression in response to anger stimuli, nine BD and four SCZ (P = 0.13) patients showed congruent facial expression in response to sadness stimuli, 14 BD and seven SCZ (P = 0.01) patients showed congruent facial expressions in response to disgust stimuli, 18 BD and 14 SCZ (P = 0.43) patients showed congruent facial expression in response to amusement stimuli (amusement stimuli were showed twice; Table 5).
Table 5

Patients that expressed congruent facial expression in response to video clips stimuli

Bipolar disorder group
Schizophrenic group
P-value
N%N%
Neutrality15100%15100%
Amusement960%640%0.46
Fear746.6%213.3%0.10
Surprise320%426.6%0.45
Anger533.3%320%0.68
Sadness960%426.6%0.13
Disgust1493.3%746.6%0.01*
Amusement960%853.3%1.00

Note:

P < 0.05.

Discussion

To our knowledge, this is the first study investigating and comparing the facial expression of patients with SCZ and BD using the FACS system. As expected, healthy controls showed more appropriate emotional experience and facial expression than patient groups (Figures 3–5). This finding partially confirms the hypothesis that BD patients, as well as SCZ patients, present reduced levels of facial expressivity presumably attributable to deficit of emotional processing and SC. SCZ patients presented a more compromised facial expression than BD patients (Figure 5). This issue is consistent with existing data: previous studies already found that deficits in expressing emotions are often present in SCZ patients and correlate with neuroleptics treatment23 and the intensity of negative symptoms (in particular with the affective flattening).24 The only significant difference between patients’ facial expression in reaction to video clips was found for the expression of disgust (Table 5): one BD and eight SCZ patients (P = 0.01) showed incongruent facial expression in response to disgust stimuli represented by scenes from the “Pink Flamingos” film. This issue is consistent with a previous study of Kholer et al25 where it was found that SCZ patients had more severe impairment in relation to specific emotions such as amusement, fear, and disgust. The deficit in the expression of disgust highlights some possible new evidence with respect to the relationship between neuroanatomy of SCZ. Functional neuroimaging research demonstrated that facial expressions of disgust engage the insular cortex more consistently than other facial expressions;26 furthermore, several studies found that lesions in the insular cortex compromise the capacity of recognizing and expressing the disgust emotion.27–29 The insular cortex is believed to be involved in consciousness and plays a role in diverse functions including perception, motor control, self-awareness, cognitive functioning, and interpersonal experience.30–33 There is an increasingly amount of data suggesting possible hypofunctioning of the insular cortex in SCZ patients,34,35 while there is no data about its possible involvement in BD. As the disgust emotion is mainly elaborated in the insular cortex, the incongruent expression of disgust of SCZ patients could be seen as further evidence of a deficit of the functionality of the insular cortex in SCZ. The results of the post film questionnaires indicated that BD and SCZ patients seem to present similar relevant impairment in recognizing and experiencing emotions: there was no significant difference between the results of the two groups of patients (both of them having significantly worse results than healthy controls; Figures 3 and 4). Difficulty in recognizing and experiencing emotions observed through the facial expression in patients could reflect the impairment in SC recently described in both SCZ and BD.1,14 Frommann et al, Marsh et al, and Lewandowski et al all found that emotional processing and social cognition in SCZ can be improved through targeted remediation training.36–38 This training could potentially be used to improve the global functioning of both SCZ and BD patients in addition to medications and psychotherapies.

Limitations

The small number of participants is a major limitation of the study; for this reason, the results should be considered preliminary. Moreover, the coders were not blinded about the status of patients. The choice to reduce the power of FACS to a binary number (expression prototype present or absent) makes it a less sensitive measure and as such different degrees of more refined and subtle facial movements could not be evaluated. This step was deemed necessary, however, as it reduced the possibility of codification bias. Further studies are needed to further assess differences and similarities in emotional responses in BD, SCZ, and other psychiatric diseases.
  32 in total

1.  Is cognitive enhancement therapy equally effective for patients with schizophrenia and schizoaffective disorder?

Authors:  Kathryn E Lewandowski; Shaun M Eack; Susan S Hogarty; Deborah P Greenwald; Matcheri S Keshavan
Journal:  Schizophr Res       Date:  2010-12-17       Impact factor: 4.939

Review 2.  Factors affecting interindividual differences in clozapine response: a review and case report.

Authors:  Francesco Saverio Bersani; Enrico Capra; Amedeo Minichino; Rossella Pannese; Nicoletta Girardi; Isabella Marini; Roberto Delle Chiaie; Massimo Biondi
Journal:  Hum Psychopharmacol       Date:  2011-04       Impact factor: 1.672

3.  Disgust implicated in obsessive-compulsive disorder.

Authors:  R Sprengelmeyer; A W Young; I Pundt; A Sprengelmeyer; A J Calder; G Berrios; R Winkel; W Vollmöeller; W Kuhn; G Sartory; H Przuntek
Journal:  Proc Biol Sci       Date:  1997-12-22       Impact factor: 5.349

4.  Cognitive impairment and functional outcome in schizophrenia and bipolar disorder.

Authors:  Michael F Green
Journal:  J Clin Psychiatry       Date:  2006-10       Impact factor: 4.384

5.  Lack of insula reactivity to aversive stimuli in schizophrenia.

Authors:  Clas Linnman; Garth Coombs; Donald C Goff; Daphne J Holt
Journal:  Schizophr Res       Date:  2012-11-30       Impact factor: 4.939

6.  Social dysfunction in bipolar disorder: pilot study.

Authors:  Cristiana Castanho de Almeida Rocca; Marcia Britto de Macedo-Soares; Clarice Gorenstein; Renata Sayuri Tamada; Cilly Kluger Issler; Rodrigo Silva Dias; Angela Maria Schwartzmann; Beny Lafer
Journal:  Aust N Z J Psychiatry       Date:  2008-08       Impact factor: 5.744

7.  The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence.

Authors:  Mauricio Tohen; Carlos A Zarate; John Hennen; Hari-Mandir Kaur Khalsa; Stephen M Strakowski; Priscilla Gebre-Medhin; Paola Salvatore; Ross J Baldessarini
Journal:  Am J Psychiatry       Date:  2003-12       Impact factor: 18.112

8.  Correlation between insula activation and self-reported quality of orgasm in women.

Authors:  Stephanie Ortigue; Scott T Grafton; Francesco Bianchi-Demicheli
Journal:  Neuroimage       Date:  2007-05-25       Impact factor: 6.556

9.  Neurocognitive basis of impaired empathy in schizophrenia.

Authors:  Simone G Shamay-Tsoory; Syvan Shur; Hagai Harari; Yechiel Levkovitz
Journal:  Neuropsychology       Date:  2007-07       Impact factor: 3.295

10.  Comparison of facial expression in patients with obsessive-compulsive disorder and schizophrenia using the Facial Action Coding System: a preliminary study.

Authors:  Giuseppe Bersani; Francesco Saverio Bersani; Giuseppe Valeriani; Maddalena Robiony; Annalisa Anastasia; Chiara Colletti; Damien Liberati; Enrico Capra; Adele Quartini; Elisa Polli
Journal:  Neuropsychiatr Dis Treat       Date:  2012-12-18       Impact factor: 2.570

View more
  10 in total

1.  Computerized analysis of facial expressions in serious mental illness.

Authors:  Tovah Cowan; Michael D Masucci; Tina Gupta; Claudia M Haase; Gregory P Strauss; Alex S Cohen
Journal:  Schizophr Res       Date:  2022-01-22       Impact factor: 4.939

2.  Facial Affective Behavior in Borderline Personality Disorder Indicating Two Different Clusters and Their Influence on Inpatient Treatment Outcome: A Preliminary Study.

Authors:  Gerhard Dammann; Myriam Rudaz; Cord Benecke; Anke Riemenschneider; Marc Walter; Monique C Pfaltz; Joachim Küchenhoff; John F Clarkin; Daniela J Gremaud-Heitz
Journal:  Front Psychol       Date:  2020-07-29

3.  Emotional Intelligence and resilience in mental health professionals caring for patients with serious mental illness.

Authors:  Beatrice Frajo-Apor; Silvia Pardeller; Georg Kemmler; Alex Hofer
Journal:  Psychol Health Med       Date:  2015-12-18       Impact factor: 2.423

4.  Prefronto-cerebellar transcranial direct current stimulation improves visuospatial memory, executive functions, and neurological soft signs in patients with euthymic bipolar disorder.

Authors:  Amedeo Minichino; Francesco Saverio Bersani; Laura Bernabei; Francesco Spagnoli; Lucilla Vergnani; Alessandra Corrado; Ines Taddei; Massimo Biondi; Roberto Delle Chiaie
Journal:  Neuropsychiatr Dis Treat       Date:  2015-08-28       Impact factor: 2.570

5.  Prefronto-cerebellar transcranial direct current stimulation improves sleep quality in euthymic bipolar patients: a brief report.

Authors:  Amedeo Minichino; Francesco Saverio Bersani; Francesco Spagnoli; Alessandra Corrado; Francesco De Michele; Wanda Katharina Calò; Martina Primavera; Baoran Yang; Laura Bernabei; Francesco Macrì; Lucilla Vergnani; Massimo Biondi; Roberto Delle Chiaie
Journal:  Behav Neurol       Date:  2014-12-07       Impact factor: 3.342

6.  Development of an Emotion-Sensitive mHealth Approach for Mood-State Recognition in Bipolar Disorder.

Authors:  Henning Daus; Timon Bloecher; Ronny Egeler; Richard De Klerk; Wilhelm Stork; Matthias Backenstrass
Journal:  JMIR Ment Health       Date:  2020-07-03

7.  Eye gaze and facial displays of emotion during emotional film clips in remitted patients with bipolar disorder.

Authors:  Hanne Lie Kjærstad; Caroline Kamp Jørgensen; Ingrid Broch-Due; Lars Vedel Kessing; Kamilla Miskowiak
Journal:  Eur Psychiatry       Date:  2020-02-27       Impact factor: 5.361

8.  Prefrontocerebellar transcranial direct current stimulation increases amplitude and decreases latency of P3b component in patients with euthymic bipolar disorder.

Authors:  Francesco Saverio Bersani; Amedeo Minichino; Francesco Fattapposta; Laura Bernabei; Francesco Spagnoli; Daniela Mannarelli; Marta Francesconi; Caterina Pauletti; Alessandra Corrado; Lucilla Vergnani; Ines Taddei; Massimo Biondi; Roberto Delle Chiaie
Journal:  Neuropsychiatr Dis Treat       Date:  2015-11-19       Impact factor: 2.570

9.  Automated Computer Vision Assessment of Hypomimia in Parkinson Disease: Proof-of-Principle Pilot Study.

Authors:  Avner Abrami; Steven Gunzler; Camilla Kilbane; Rachel Ostrand; Bryan Ho; Guillermo Cecchi
Journal:  J Med Internet Res       Date:  2021-02-22       Impact factor: 5.428

10.  Facial and Vocal Markers of Schizophrenia Measured Using Remote Smartphone Assessments: Observational Study.

Authors:  Anzar Abbas; Bryan J Hansen; Vidya Koesmahargyo; Vijay Yadav; Paul J Rosenfield; Omkar Patil; Marissa F Dockendorf; Matthew Moyer; Lisa A Shipley; M Mercedez Perez-Rodriguez; Isaac R Galatzer-Levy
Journal:  JMIR Form Res       Date:  2022-01-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.